众生药业
(002317)
| 流通市值：99.92亿 | | | 总市值：111.72亿 |
| 流通股本：7.62亿 | | | 总股本：8.52亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,908,022,039.84 | 1,364,366,722.8 | 641,123,852.5 | 2,610,550,120.98 |
| 营业收入 | 1,908,022,039.84 | 1,364,366,722.8 | 641,123,852.5 | 2,610,550,120.98 |
| 利息收入 | 0 | 0 | 0 | 0 |
| 已赚保费 | 0 | 0 | 0 | 0 |
| 手续费及佣金收入 | 0 | 0 | 0 | 0 |
| 二、营业总成本 | 1,701,672,490.4 | 1,174,830,188.15 | 564,699,468.91 | 2,295,496,923.31 |
| 营业成本 | 837,942,033.19 | 587,700,660.15 | 278,952,444.18 | 1,080,875,266.25 |
| 利息支出 | 0 | 0 | 0 | 0 |
| 手续费及佣金支出 | 0 | 0 | 0 | 0 |
| 退保金 | 0 | 0 | 0 | 0 |
| 赔付支出净额 | 0 | 0 | 0 | 0 |
| 提取保险合同准备金净额 | 0 | 0 | 0 | 0 |
| 保单红利支出 | 0 | 0 | 0 | 0 |
| 分保费用 | 0 | 0 | 0 | 0 |
| 税金及附加 | 17,097,576.55 | 13,588,445.51 | 6,931,422.23 | 24,924,861.82 |
| 销售费用 | 645,880,775.21 | 442,514,542.78 | 213,627,193.97 | 889,897,441.5 |
| 管理费用 | 108,472,335.72 | 69,542,088.11 | 32,986,828.28 | 155,646,170.02 |
| 研发费用 | 86,091,412.48 | 57,459,831.33 | 29,971,407.45 | 127,369,021.12 |
| 财务费用 | 6,188,357.25 | 4,024,620.27 | 2,230,172.8 | 16,784,162.6 |
| 其中:利息费用 | 23,244,729.18 | 16,124,838.53 | 8,523,068.11 | 46,911,917.65 |
| 其中:利息收入 | 16,279,711.69 | 12,875,010.48 | 6,487,063.08 | 30,610,022.03 |
| 加:公允价值变动收益 | 5,861,092.4 | -47,816,614.28 | -25,497,155.37 | -65,230,754.23 |
| 加:投资收益 | 20,840,773.22 | 15,260,783.66 | 7,168,129.28 | 23,528,489.75 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 28,175.01 | 28,175.01 | 0 | 21,684,431.17 |
| 资产减值损失(新) | -919,357.81 | -919,357.81 | -1,506,358.31 | -16,746,461.11 |
| 信用减值损失(新) | -6,935,540.55 | -5,448,897.53 | -532,781.49 | 398,937.31 |
| 其他收益 | 11,105,582.16 | 6,927,841.9 | 3,217,671.73 | 20,042,986.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 236,330,273.87 | 157,568,465.6 | 59,273,889.43 | 298,730,827.02 |
| 加:营业外收入 | 89,504.82 | 62,513.97 | 13,577.21 | 1,192,790.46 |
| 减:营业外支出 | 58,696,945.18 | 58,023,326.18 | 170,841.41 | 16,266,738.17 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 177,722,833.51 | 99,607,653.39 | 59,116,625.23 | 283,656,879.31 |
| 减:所得税费用 | 41,811,969.92 | 20,773,362.87 | 10,405,699.02 | 33,755,938.41 |
| 六、净利润 | 135,910,863.59 | 78,834,290.52 | 48,710,926.21 | 249,900,940.9 |
| 持续经营净利润 | 135,910,863.59 | 78,834,290.52 | 48,710,926.21 | 249,900,940.9 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | 148,802,427.39 | 87,409,781.47 | 51,293,866.37 | 263,273,179.73 |
| 少数股东损益 | -12,891,563.8 | -8,575,490.95 | -2,582,940.16 | -13,372,238.83 |
| (一)基本每股收益 | 0.18 | 0.1 | 0.06 | 0.32 |
| (二)稀释每股收益 | 0.18 | 0.1 | 0.06 | 0.32 |
| 八、其他综合收益 | -448,465.64 | -145,671.64 | 605,085.13 | 2,913,314.44 |
| 归属于母公司股东的其他综合收益 | -448,465.64 | -145,671.64 | 605,085.13 | 2,913,314.44 |
| 九、综合收益总额 | 135,462,397.95 | 78,688,618.88 | 49,316,011.34 | 252,814,255.34 |
| 归属于母公司股东的综合收益总额 | 148,353,961.75 | 87,264,109.83 | 51,898,951.5 | 266,186,494.17 |
| 归属于少数股东的综合收益总额 | -12,891,563.8 | -8,575,490.95 | -2,582,940.16 | -13,372,238.83 |
| 公告日期 | 2024-10-29 | 2024-08-30 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |